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Abstract
With the re-emergence of older antibiotics as valuable choices for treatment of serious infections, we studied the
aminoglycoside resistance of Gram-negative bacteria isolated from patients with ear, urinary tract, skin, and gastrointestinal
tract infections at Minia university hospital in Egypt. Escherichia coli (mainly from urinary tract and gastrointestinal tract
infections) was the most prevalent isolate (28.57%), followed by Pseudomonas aeruginosa (25.7%) (mainly from ear
discharge and skin infections). Isolates exhibited maximal resistance against streptomycin (83.4%), and minimal resistance
against amikacin (17.7%) and intermediate degrees of resistance against neomycin, kanamycin, gentamicin, and tobramycin.
Resistance to older aminoglycosides was higher than newer aminoglycoides. The most common aminoglycoside resistance
phenotype was that of streptomycin resistance, present as a single phenotype or in combination, followed by kanamycin-
neomycin as determined by interpretative reading. The resistant Pseudomonas aeruginosa strains were capable of producing
aminoglycoside-modifying enzymes and using efflux as mechanisms of resistance. Using checkerboard titration method, the
most frequently-observed outcome in combinations of aminoglycosides with b-lactams or quinolones was synergism. The
most effective combination was amikacin with ciprofloxacin (100% Synergism), whereas the least effective combination was
gentamicin with amoxicillin (53.3% Synergistic, 26.7% additive, and 20% indifferent FIC indices). Whereas the studied
combinations were additive and indifferent against few of the tested strains, antagonism was never observed. The high
resistance rates to aminoglycosides exhibited by Gram-negative bacteria in this study could be attributed to the selective
pressure of aminoglycoside usage which could be controlled by successful implementation of infection control measures.
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Introduction
Aminoglycosides are broad-spectrum antibiotics of high potency
that have been traditionally used for the treatment of serious
Gram-negative infections [1]. They kill bacteria by inhibiting
protein synthesis via binding to the 16S rRNA and by disrupting
the bacterial cell membrane integrity [2]. The year 1944 marked
the beginning of the aminoglycoside era with streptomycin being
introduced, and was followed by the discovery of a series of
milestone aminoglycosides such as kanamycin, gentamicin, and
tobramycin [3]. The semi-synthetic aminoglycosides, dibekacin,
amikacin, and netilmicin, which were introduced in the seventies,
allowed clinicians to overcome the anti-aminoglycoside resistance
acquired by some bacterial strains against some earlier aminogly-
cosides [3]. There has been a recent trend towards using older
antibiotics, such as aminoglycosides in the management and
treatment of serious infections that are difficult to treat [4]. The
reason is that the relative low-level use of older antibiotics could
have contributed to preservation of activity against many bacterial
isolates, which are becoming more resistant to newer more-
frequently used antibacterial agents [4]. Thus, in this study we
explored the aminoglycoside resistance patterns of bacterial
isolates of patients with different infectious diseases at Minia
university hospital in Egypt.
There are several mechanisms that contribute to the development
of aminoglycoside resistance. These include the deactivation of
aminoglycosides by aminoglycoside-modifying enzymes which act
on specific sites of the aminoglycosides causing acetylation via
aminoglycoside acetyltransferase (AAC), adenylation via aminogly-
coside nucleotdyltransferase (ANT) or phosphorylation via amino-
glycoside phosphotransferase (APH) [2,5,6]. This is a major
mechanism by which clinical isolates of Gram-negative and Gram-
positive bacteria cause an enzymatic modification of the amino or
hydroxyl groups aminoglycosides, causing them to bind poorly to
ribosomes and thus fail to trigger energy-dependent phase II, which
allows bacteria to survive [7]. Other mechanisms include the
reduction of the intracellular concentration of aminoglycosides by
changes in the outer membrane permeability which is usually a non-
specific resistance mechanism, inner membrane transport, active
efflux or drug trapping, the alteration of the 30S ribosomal subunit
target by mutation, and finally methylation of the aminoglycoside
binding site [2]. The efflux system has been specifically shown to be
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infections in several countries [8,9,10]. Thus, we tested if this
resistance mechanism was operational in the isolates.
Antimicrobial synergy resulting from combination antibiotic
therapy has been a preferred therapeutic approach to treat serious
bacterial infections by broadening antibacterial spectrum and
preventing the development of resistance. Thus, we tested if
aminoglycosides still retained their characteristic ability of
producing synergistic bactericidal activity against Escherichia coli
isolates in combination with antibiotics inhibiting cell wall
biosynthesis, such as b-lactams [11].
Materials and Methods
Sample collection
A total of 250 clinical samples were examined; 115 from
patients with ear infections (purulent ear discharge), 66 from urine
of patients with urinary tract infections, 44 from patients with skin
infections (wounds, abscesses, and burn exudates), and 25 from
stool of patients with Gastrointestinal tract infections were
collected from patients at Minia University Hospital in Egypt in
the period from 2007 to 2009. Among these, 175 Gram-negative
bacterial isolates were identified and recovered using standard
microbiological procedures. Moreover, samples were examined for
P. aeruginosa by polymerase chain reaction, as described previously
[12,13,14].
Minia University Hospital is a major hospital in Upper Egypt
and is the only academic hospital in Minia governorate
(population of about 4 millions). It serves patients referred to it
from other smaller hospitals in Minia and its surrounding towns
and villages in Upper Egypt.
Ethics Statement
Ethical approval to perform the study was obtained from the
institutional review board of Minia University. Written informed
consent was obtained from all patients included in the study.
Antimicrobial susceptibility
Both agar dilution and disk diffusion methods were used to test
the susceptibility of the strains to streptomycin (Sigma-Aldrich,
USA), neomycin (Sigma), kanamycin (Sigma), gentamicin (Sigma),
and amikacin (Bristol-Myers Squibb, USA) according to Clinical
and Laboratory Standards Institute procedures, 2007 [15]. Disks
for streptomycin (10 mg), neomycin (30 mg), kanamycin (30 mg),
gentamicin (10 mg), amikacin (30 mg), and tobramycin (10 mg)
(Oxoid, UK) were used in the disk diffusion method.
Interpretative reading
By testing the susceptibility of the isolates against a range of
aminoglycoside antibiotics, determining the aminoglycoside resis-
tance patterns can be used to infer resistance phenotypes and
possible aminoglycoside modifying enzymes. This method has
been referred as interpretative reading [16].
Detection of aminoglycoside-modifying enzymes by agar
diffusion
We used a protocol modified from Benveniste and Davies’s
method [17]. Briefly, a crude enzyme extract was prepared from
the aminoglycoside-resistant Pseudomonas aeruginosa strain (S40). For
a total of 50 ml reaction mixture, 25 ml of the enzyme extract
(containing 1 mg/ml protein) was incubated in the presence of 22
nmoles of the tested aminoglycoside antibiotics, 50 nmoles
dithiotheriotol (Sigma), 2.5 mmoles tris pH 8.1 (Sigma), 120
nmoles ATP (Sigma) and 0.4 mmoles Magnesium chloride
(BDH, UK). To monitor the extent of inactivation of the
antibiotics, 10 ml of the reaction mixture (with and without the
enzyme extract) was spotted on filter paper disks, which were
placed on Mueller-Hinton agar plates seeded with a sensitive
standard Pseudomonas aeruginosa PAOI strain. Plates were incubated
at 37uC for 24 hr. In case of inactivation of the antibiotics, the
presence of a crude enzyme extract reduces the inhibition zone of
antibiotics than the inhibition zone in negative control disks in the
absence of the enzyme extract (normally more than 5 mm).
Detection of the efflux system
The minimum inhibitory concentrations (MIC) of 25 MDR
Pseudomonas aeruginosa isolates were examined against streptomycin,
gentamicin, neomycin, kanamycin, and amikacin in the presence
or absence of 50 mM of the efflux inhibitor carbonyl cyanide-m-
chlorophenylhydrazone (CCCP) (Sigma) [18]. The reduction in
MIC of an antibiotic with CCCP is indicative of the presence of an
efflux system mode of resistance against this antibiotic.
Evaluation of antibiotic combination
In order to determine the potential presence of synergy that can
help overcome bacterial resistance, we used the checkerboard
titration method [19]. The aim was to test combinations of
aminoglycosides (Gentamicin and Amikacin) with b-lactams and
quinolones by broth microdiluion on 15 Escherichia coli strains. The
MIC of each of gentamicin and amikacin was determined before
and after combination with b-lactams (Amoxicillin, Cephradine,
and Cefotaxime) or quinolones (Ciprofloxacin). The fractional
inhibitory concentrations (FIC) were calculated as the MIC of
drug A and drug B in combination divided by the MIC of drug A
or drug B. The FIC index specifies whether the combination had a
synergistic, additive, indifferent, or antagonistic effect. Synergism
was defined as an FIC index of less than 0.5. Additive or
indifferent effects were defined as an FIC index of 0.5–4 (Additive
0.5–1; Indifferent 1–4). Antagonism was defined as an FIC index
of more than 4 [20]. The following antibiotics were tested at the
following concentrations: Gentamicin (2 to 1024 mg/ml); Amika-
cin and Cephradine (0.5 to 256 mg/ml); Ciprofloxacin, Amoxicil-
lin, and Cefotaxime (0.5 to 128 mg/ml).
Statistical Analysis
Statistical analysis was performed using the SPSS software
(Version 16). Chi-square test was used to compare between agar
dilution and disk diffusion methods in classifying the Gram-
negative isolates in the resistant or the susceptible category. P
values of less than 0.05 were considered to be statistically
significant.
Results
As shown in Table 1, the biochemical identification of a total of
175 Gram-negative bacterial isolates indicated the presence of 50
isolates of Escherichia coli (50/175, 28.57%), 45 isolates of
Pseudomonas aeruginosa (25.7%), 17 isolates of Serratia marcescens
(9.7%), 16 isolates of Proteus mirabilis (9.14%), 13 isolates of
Enterobacter aerogenes (7.42%), 8 isolates of Proteus vulgaris (4.57%), 8
isolates of Klebsiella pneumonia (4.57%), 8 isolates of Morganella
morganii (4.57%), 6 isolates of Citrobacter freundii (3.43%), and 4
isolates of Citrobacter koseri (2.29%). The 50 isolates of Escherichia coli
included 25 from urine, 6 from ear discharge, 6 from skin
infections, and 13 from stool. The 45 isolates of Pseudomonas
aeruginosa included 10 from urine, 25 from ear discharge, 9 from
skin infections, and one from stool. Escherichia coli was the most
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testinal tract infections, whereas Pseudomonas aeruginosa was the most
prevalent in ear discharge and skin infections.
The isolated Gram-negative bacteria showed variable degrees of
resistance to aminoglycosides as assessed by agar dilution and disk
diffusion methods (Tables 2 and 3). Isolates exhibited maximal
resistance against streptomycin (83.4%), and minimal resistance
against amikacin (17.7%) and intermediate degrees of resistance
against neomycin, kanamycin, gentamicin, and tobramycin. Chi-
square test revealed that there was no significant difference
between agar dilution and disk diffusion methods in classifying the
Gram-negative isolates in the resistant or the susceptible category
(P.0.05). It is noteworthy that, with the exception of Serratia
marcescens, resistance of Gram-negative bacteria to tobramycin was
less than resistance to gentamicin.
Interpretative reading was used to detect phenotype patterns of
aminoglycoside resistance in Gram-negative bacteria as well as
possible modifying enzymes (Table 4). The isolates were classified
as wild-type classical strains (strains which are susceptible to all
aminoglycosides with no acquired resistance mechanisms) and
resistant strains (data not shown). The resistant strains were
phenotyped according to their susceptibility patterns. As expected,
different isolates exhibited different phenotypes. However, there
were general trends that were consistent in all isolates. For
example, the most common resistance phenotype in the isolates
was that of streptomycin, which was present as a single phenotype
or in combination, followed by kanamycin-neomycin.
In order to study resistance mechanisms in more detail, we
decided to focus on Pseudomonas aeruginosa isolates, given the
scarcity of data on the antimicrobial resistance mechanisms of
Pseudomonas aeruginosa in Egypt. Results indicated that the diameters
of the inhibition zones of both gentamicin and amikacin against
the sensitive Pseudomonas strain PAO1 were reduced by the
addition of a crude enzyme extract prepared from a resistant
Pseudomonas aeruginosa strain (S40) as compared to the diameters of
inhibition zones around control disks that were not treated with
the enzyme extract (data not shown). This showed that production
of aminoglycoside-modifying enzymes was one of the mechanisms
of Pseudomonas aeruginosa resistance to aminoglycosides in this study.
Moreover, when using the efflux inhibitor CCCP, the minimum
Table 1. Prevalence of the isolated microorganisms in different sample sites.
Total number of
isolates (250)
Gastrointestinal Tract
Infections (25) Skin Infections (44)
Ear Infections
(115)
Urinary Tract
Infections (66)
50 13 (52%) 6 (13.64%) 6 (5.22%) 25 (37.88%) Escherichia coli
45 1 (4%) 9 (20.45%) 25 (21.7%) 10 (15.15%) Pseudomonas aeruginosa
17 0 (0%) 6 (13.64%) 4 (3.47%) 7 (25.75%) Serratia marscecence
16 0 (0%) 1 (2.27%) 15 (13.04%) 0 (0%) Proteus mirabilis
13 0 (0%) 2 (4.55%) 2 (1.74%) 9 (13.63%) Enterobacter aerogenes
8 0 (0%) 0 (0%) 8 (6.95%) 0 (0%) Proteus vulgaris
8 0 (0%) 3 (6.82%) 2 (1.74%) 3 (4.55%) Klebsiella pneumonia
8 0 (0%) 1 (2.27%) 2 (1.74%) 5 (7.58%) Morganella morgani
6 0 (0%) 1 (2.27%) 4 (3.47%) 1 (1.52%) Citrobacter freundii
4 0 (0%) 2 (4.55%) 2 (1.74%) 0 (0%) Citrobacter koseri
175 14 31 70 60 Total
doi:10.1371/journal.pone.0017224.t001
Table 2. Resistance patterns of Gram-negative bacteria to different aminoglycosides (Agar Dilution method).
Amikacin Gentamicin Kanamycin Neomycin Streptomycin No. of isolates Isolates
2 (4%) 20 (40%) 23 (46%) 27 (54%) 39 (78%) 50 Escherichia coli
13 (28.8%) 32 (71.1%) 41 (91.1%) 40 (88.9%) 42 (93.3%) 45 Pseudomonas aeruginosa
3 (17.6%) 7 (41.1%) 11 (64.7%) 10 (58.8%) 13 (76.4%) 17 Serratia marcescens
1 (6.3%) 2 (12.5%) 8 (50%) 6 (37.5%) 12 (75%) 16 Proteus mirabilis
6 (46.2%) 8 (61.5%) 9 (69.2%) 9 (69.2%) 11 (84.6%) 13 Enterobacter aerogenes
2 (25%) 5 (62.5%) 7 (87.5%) 6 (75%) 7 (87.5%) 8 Proteus vulgaris
2 (25%) 4 (50%) 7 (87.5%) 6 (75%) 6 (75%) 8 Klebsiella pneumonia
1 (12.5%) 5 (62.5%) 5 (62.5%) 4 (50%) 8 (100%) 8 Morganella morganii
1 (16.6%) 3 (50%) 3 (50%) 4 (66.7%) 5 (83.3%) 6 Citrobacter freundii
0 (0%) 2 (50%) 3 (75%) 3 (75%) 3 (75%) 4 Citrobacter koseri
31 (17.7%) 88 (50.3%) 117 (66.9%) 115 (65.7%) 146 (83.4%) 175 Total
*Breakpoints were: $16 mg/ml for streptomycin and neomycin, $25 mg/ml for kanamycin, $8 mg/ml for gentamicin, and $32 mg/ml for amikacin according to CLSI
(2007).
doi:10.1371/journal.pone.0017224.t002
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cin, gentamicin, neomycin, kanamycin, and amikacin) against
Pseudomonas aeruginosa isolates were reduced indicating that efflux is
a second leading mechanism of Pseudomonas aeruginosa resistance to
aminoglycosides in this study (Table 5).
One of the common ways to overcome bacterial antibiotic
resistance is the use of antibiotic combinations. In order to
evaluate the effects of combination of gentamicin and amikacin
with cefotaxime, cephradine, amoxicillin, and ciprofloxacin, we
employed the checkerboard titration method (Table 6). Synergism
was the most frequently observed outcome in all antibiotic
combinations against the tested strains. The most effective
combination was amikacin with ciprofloxacin (Synergism in all
isolates), whereas the least effective combination was gentamicin
with amoxicillin (Synergistic FIC indices in only 8 isolates; 53.3%,
additive FIC indices in 4 isolates; 26.7%, and indifferent FIC
indices in 3 isolates; 20%). Antagonism was not observed with any
combination. The studied combinations were additive and
indifferent against few of the tested strains (Table 6).
Discussion
Given the challenge of having very few newly-discovered
antibiotics in recent years and the scarcity of any recent novel
developments in the design of molecules that can inhibit the
resistant bacterial enzymes, we intended to re-evaluate the
effectiveness of aminoglycosides in the treatment of different
bacterial infections. Aminoglycosides are older antibiotic com-
pounds that, due to a general low-level use in recent years, are
claimed by some to have preserved their activities against some of
the most resistant hard-to-treat bacterial infections [4]. Moreover,
there have been reports of the effectiveness of altering the
administration dosages of aminoglycosides and/or the use of
aminoglycoside analogues in reducing their typical adverse effects,
such as nephro- and ototoxicity, while still preserving reasonable
antibacterial activities [21,22,23,24]. To the best of our knowl-
edge, this is the first study on aminoglycoside resistance in Upper
Egypt.
As evident in Tables 2 and 3, resistance to older aminoglyco-
sides such as streptomycin, neomycin, and kanamycin was
generally higher than resistance to newer aminoglycoides with
broader spectra of antibacterial activity [11], such as gentamicin,
amikacin, and tobramycin. This suggests that the implementation
of newer aminoglycosides could still be the gold standard for
treatment in cases of more resistant bacteria and could be
especially useful in cases of mixed infections.
Amikacin is a derivative of kanamycin A with the amino group
at position 1 acylated by 4-amino-2-hydroxybutyrate [25]. In this
study, amikacin was more active against Gram-negative bacteria
than other tested aminoglyside antibiotics (Tables 2 and 3), which
is consistent with results from other studies [24,26]. The high
activity of amikacin observed in this study may be attributed to the
presence of the aminohydroxybutyryl group, which generally
prevents the enzymatic modification of amikacin at multiple
positions without interfering with binding to the A site of rRNA
[25].
It is noteworthy that other researchers have detected much
higher rates of resistance of Gram-negative bacteria to amikacin in
Turkey (49.7%) and in India (55.1%) [27,28]. However, these
resistance rates were still lower than resistance rates to tobramycin
in Turkey (82.4%) and India (83.6%) [27,28]. Resistance to
gentamicin varied in different countries with very high resistance
rates (94.5%) reported in Turkey compared to much lower
resistance rates (32.6%) reported in India [27,28].
Although the AAC(69)-I enzyme was absent or rarely found in
most isolates in this study (Table 4), it was the most prevalent
enzyme in other studies [28]. The synthesis of more than one
enzyme simultaneously led to various composite phenotypes that
increased the number of resistant strains that we observed. In this
study and in other studies, the most frequent resistance phenotype
was that of streptomycin for Escherichia coli, Klebsiella pneumonia, and
Proteus species [29]. On the other hand, the most common resistance
phenotype for Enterobacter species in a study performed in Greece
was that of kanamycin-neomycin [29]. The different resistance
patterns in different geographical regions may be related to
differences in antibiotic (aminoglycoside) treatment regimens.
The high resistance rates to aminoglycosides exhibited by
Gram-negative bacteria in this study could be attributed to the
selective pressure of aminoglycoside usage [2]. Resistance of
Pseudomonas aeruginosa to antipseudomonal aminoglycosides, such as
gentamicin, tobramycin, and amikacin has been reported in most
parts of the world [30]. Data indicating negative effects of CCCP
on resistance of selected Pseudomonas aeruginosa isolates (Table 5) is
consistent with data from recent studies on Pseudomonas aeruginosa
resistance patterns in Egypt [12].
The checkerboard titration method was employed to check if it
was possible to overcome aminoglycoside resistance in Gram-
negative bacteria (Table 6). Fortunately, aminoglycosides such, as
Table 3. Resistance patterns of Gram-negative bacteria to different aminoglycosides (Disk Diffusion method).
Tobramycin Amikacin Gentamicin Kanamycin Neomycin Streptomycin No. of isolates Isolates
15 (30%) 8 (16%) 18 (36%) 22 (44%) 24 (48%) 41 (82%) 50 Escherichia coli
10 (22.2%) 9 (20%) 25 (55.6%) 36 (80%) 35 (77.8%) 40 (88.9%) 45 Pseudomonas aeruginosa
4 (23.5%) 1 (5.9%) 3 (17.6%) 9 (52.9%) 10 (58.8%) 12 (70.7%) 17 Serratia marcescens
2 (12.5%) 1 (6.25%) 2 (12.5%) 8 (50%) 8 (50%) 13 (81.3%) 16 Proteus mirabilis
5 (38.5%) 4 (30.8%) 6 (46.2%) 8 (61.5%) 8 (61.5%) 10 (76.9%) 13 Enterobacter aerogenes
3 (37.5%) 2 (25%) 4 (50%) 7 (87.5%) 7 (87.5%) 8 (100%) 8 Proteus vulgaris
4 (50%) 2 (25%) 5 (62.5%) 6 (75%) 5 (62.5%) 7 (87.5%) 8 Klebsiella pneumonia
2 (25%) 1 (12.5%) 3 (37.5%) 5 (62.5%) 5 (62.5%) 6 (75%) 8 Morganella morganii
1 (16.7%) 1 (16.7%) 2 (33.3%) 3 (50%) 3 (50%) 4 (66.7%) 6 Citrobacter freundii
0 (0%) 0 (0%) 0 (0%) 2 (50%) 3 (75%) 2 (50%) 4 Citrobacter koseri
46 (26.3%) 30 (17.1%) 68 (38.8%) 106 (60.6%) 108 (61.7%) 143 (81.7%) 175 Total
doi:10.1371/journal.pone.0017224.t003
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synergistic activity when used in combination with b-lactams
(Table 6). This indicated that Gram-negative organisms are still
sensitive to this antibiotic combination, as they were for more than
thirty years [31,32]. This synergism of aminoglycosides with b-
lactams or quinolones could be due to the enhanced intracellular
uptake of aminoglycosides facilitated by cell wall synthesis
inhibitors that increase bacterial permeability [11].
In the clinic, there have been several reports of increased
adverse effects in aminoglycoside-b-lactam combination therapy
Table 5. Effect of adding CCCP on antibiotic resistance pattern of Pseudomonas aeruginosa isolates.
Amikacin Gentamicin Kanamycin Neomycin Streptomycin
Isolate
number
MIC in
presence
of 10 mM
CCCP (mg/L)
MIC
(mg/L)
MIC in
presence
of 10 mM
CCCP (mg/L)
MIC
(mg/L)
MIC in
presence
of 10 mM
CCCP (mg/L)
MIC
(mg/L)
MIC in
presence
of 10 mM
CCCP (mg/L)
MIC
(mg/L)
MIC in
presence
of 10 mM
CCCP (mg/L)
MIC
(mg/L)
0.5 4 2 16 8 32 16 32 4 32 1
0.25 0.5 2 128 8 64 64 128 8 64 2
2 16 2 512 8 512 32 512 8 1024 3
0 . 5 2 1 3 24 3 24 6 44 6 44
4 32 0.5 16 4 32 4 32 8 1024 5
4 16 2 32 8 128 8 128 8 64 6
4 32 2 8 8 32 8 64 8 1024 7
2 16 2 256 8 256 8 256 4 32 8
4 32 2 256 32 32 8 16 4 32 9
1 1 61 1 68 6 48 6 44 3 21 0
1 16 1 8 8 128 8 128 8 64 11
2 16 1 1024 64 256 64 128 8 512 12
4 128 0.5 32 32 64 8 64 4 32 13
2 16 1 1024 8 512 8 512 8 32 14
2 16 1 16 8 256 8 256 8 32 15
4 64 2 1024 16 32 4 32 8 128 16
2 32 2 8 32 256 16 128 8 64 17
2 32 2 32 32 64 32 64 32 64 18
4 3 22 3 28 6 48 3 28 6 41 9
4 16 2 128 8 512 8 128 8 64 20
4 64 2 128 128 1024 128 1024 512 1024 21
4 32 2 32 32 64 4 128 64 1024 22
4 3 22 2 5 6 8 6 48 6 48 6 42 3
4 32 2 64 32 64 16 32 8 64 24
1 4 2 128 32 64 16 64 8 64 25
doi:10.1371/journal.pone.0017224.t005
Table 4. Aminoglycoside resistance phenotype and mechanism of Gram-negative bacteria (Interpretative Reading method).
Pseudomonas
aeruginosa
Morganella
morganii
Klebsiella
pneumonia
Citrobacter
species
Enterobacter
aerogenes
Proteus
species
Serratia
marcescens
Escherichia
coli Mechanism
Aminoglycoside
Resistance
Phenotype
73.33% 62.5% 62.5% 50% 46.2% 75% 70.6% 62% ANT(30)- I S
62.22% 50% 37.5% 40% 30.85% 50% 52.9% 20% APH(39)- I K, Nm
2.22% 12.5% 25% 0% 7.7% 8.33% 17.6% 8% ANT(20)- I K, T, G
48.9% 12.5% 12.5% 10% 7.7% 8.33% 0% 2% AAC(39)- I G
4.44% 0% 0% 0% 0% 0% 5.9% 0% AAC(69)- I T, A
15.6% 12.5% 25% 10% 30.8% 12.5% 0% 20% Impermeability S, K, Nm, G, T, A
*S, Streptomycin; K, Kanamycin; Nm, Neomycin; G, Gentamicin; T, Tobramycin; A, Amikacin.
AAC, Acetyltransferase; ANT, nucleotidyltransferase or adenylyltransferase; APH, Phosphotransferase
doi:10.1371/journal.pone.0017224.t004
Aminoglycoside Resistance of Gm-Negative Bacteria
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17224over b-lactam monotherapy [33,34,35,36]. Thus, the decision for
clinical implementation of empirical combination antibiotic
therapy has to be taken with caution and should only be reserved
for patients with resistant Gram-negative infections, when the
benefits of synergistic antibiotic activity potentially outweigh the
risks of increased side effects. Successful implementation of
infection control measures is a must to reduce the problem of
bacterial resistance, especially in countries where patients can have
access to antibiotics without a prescription.
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